Orange Book product · Brand (NDA)
POTASSIUM PHOSPHATES
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
At a glance
Sep 19, 2019
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 19, 2019
6 yr 10 mo ago
Today
Patent 10632150 expires
Listed drug product patent expiration.
Apr 19, 2039
in 13 yr
Pharmaceutical detail
Active ingredient
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
Strength
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)
Dosage form
SOLUTION
Route
INTRAVENOUS
TE code
Not listed
Application
NDA 212121
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2024POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDEBrand (NDA)
NDA 218343 · AMNEAL
- 2019POTASSIUM PHOSPHATESBrand (NDA)
NDA 212832 · FRESENIUS KABI USA
- 2026POTASSIUM PHOSPHATESGeneric (ANDA)
ANDA 220373 · CAPLIN
- 2025POTASSIUM PHOSPHATESGeneric (ANDA)
ANDA 217459 · HOSPIRA
- 2025POTASSIUM PHOSPHATESGeneric (ANDA)
ANDA 217892 · CIPLA
- 2024POTASSIUM PHOSPHATESGeneric (ANDA)
ANDA 217726 · SOMERSET THERAPS LLC
- 2023POTASSIUM PHOSPHATESGeneric (ANDA)
ANDA 216344 · AMNEAL
- 2023POTASSIUM PHOSPHATESGeneric (ANDA)
ANDA 216274 · AM REGENT
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 10632150 | Apr 19, 2039 | in 13 yr | ProductU-2789 |

